Rheumatoid Arthritis (RA) Market is expected to grow at a CAGR of 3.3% till 2021 in Asia - Pacific Region

1
Rheumatoid Arthritis Therapeutics in Asia-
Pacific Markets to 2021- Novel IL- 6 and JAK
Inhibitors to Stimulate Moderate Growth Despite
Brand Erosion of Blockbuster Anti- TNFs
Published on 01 May, 2015 Number of pages
126 Single User Price 4995
The value of the Rheumatoid Arthritis(RA) Market
in the APAC region amounted to an estimated 5.6
billion in 2014 and is expected to register a
Compound Annual Growth Rate (CAGR) of 3.3 to
reach 6.9 billion by 2021.
2
Summary of the ReportMIR Research, the leading
business intelligence provider, has released its
latest research, "Rheumatoid Arthritis
Therapeutics in Asia-Pacific Markets to 2021 -
Novel IL-6 and JAK Inhibitors to Stimulate
Moderate Growth Despite Brand Erosion of
Blockbuster Anti-TNFs", which provides in-depth
analysis of Rheumatoid Arthritis (RA) market
within the Asia-Pacific (APAC) market covering
the four countries of Australia, China, India and
Japan. The report provides an estimation of
market size for 2014, along with market forecast
until 2021 The value of the RA market in the
APAC region amounted to an estimated 5.6 billion
in 2014 and is expected to register a Compound
Annual Growth Rate (CAGR) of 3.3 to reach 6.9
billion by 2021. The key drivers for growth in
the APAC market include the increasing prevalent
population and the anticipated market launch of
promising pipeline candidates. The late-stage
pipeline which has a potential to stimulate
growth during the forecast period include
interleukin (IL)-6 inhibitors Sanofi/Regenerons
sarilumab, Johnson Johnson/GlaxoSmithKlines
JJ/GSKs sirukumab, small molecules (four
janus kinase JAK inhibitors Eli Lilly/Incytes
baricitinib, Loss of patent exclusitivity of
major second-line biologic anti-TNF during such
as Enbrel, Remicade and Humira by the end of the
forecast period is the major barrier for growth
in the RA market size in the APAC markets.
Click Here To Check Complete Report
3

• Scope of the Report
• The report analyzes treatment usage patterns,
  drug types available and pipeline and market
  forecasts for RA. It covers and includes -
• A brief introduction to RA, including the
  diseases pathophysiology, risk factors,
  diagnosis and an overview of pharmacotherapy and
  treatment algorithms.
• In-depth analysis of the drug combinations used
  in the treatment of RA, including analyses of
  their safety, efficacy, and place in the disease
  treatment algorithm, as well as a heat map
  comparing the drug combinations in terms of
  safety and efficacy
• A comprehensive review of the pipeline for OC
  therapies, including individual analysis of a
  number of late-stage pipeline drugs that have the
  potential to enter the market in the forecast
  period the pipeline is analyzed on the basis of
  phase distribution, molecule type and molecular
  target, and route of administration
• Additional in-depth analysis of pipeline drug
  clinical trials by phase, molecule type, trial
  size, and trial duration, and program failure
  rate analyses for each molecule type and
  mechanism of action
• Multi-scenario forecast market data to 2021,
  taking into account how it will be affected by
  the introduction of new drugs, the expiry of key
  patents on current drugs, and the changes in
  disease epidemiology across the APAC markets

Download Sample Brochure
4

• Reasons to buy
• Primarily, the report will allow clients to gain
  a strong understanding of RA, helping to identify
  and clarify market opportunities and the
  competitive environment. It will also allow you
  to -
• Understand the RA pipeline and the key trends in
  the current product development landscape
• Observe detailed profiles for the promising
  pipeline products, including revenue forecasts,
  and gain an insight into how they are likely to
  compete in the market, and what their main
  competitors will be
• Follow the trends in RA clinical trial size and
  duration in relation to industry averages and
  assess the potential risk of future developmental
  programs for RA therapeutics, depending on the
  mechanism of action, by considering the recorded
  clinical trial failure rates
• Observe the potential growth patterns expected
  for the RA market over the forecast period, and
  identify which countries are expected to make the
  biggest contribution to this growth.

Make an Inquiry Before Buying
5
Rheumatoid Arthritis Therapeutics in Asia-
Pacific Markets to 2021- Novel IL- 6 and JAK
Inhibitors to Stimulate Moderate Growth Despite
Brand Erosion of Blockbuster Anti- TNFs
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Rheumatoid Arthritis(RA) Market are provided
in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Rheumatoid
Arthritis(RA) Market Report